![]() |
NOBELFÖRSAMLINGEN KAROLINSKA INSTITUTET
THE NOBEL ASSEMBLY AT THE KAROLINSKA INSTITUTE
The Nobel Assembly of
Karolinska Institutet has today decided to award the
Nobel Prize in Physiology or Medicine for 1984 jointly
to
Niels K. Jerne, Georges J.F. Köhler and César
Milstein
for theories concerning "the specificity in development and
control of the immune system" and the discovery of "the
principle for production of monoclonal antibodies".
Niels K. Jerne is the great theoretician in
immunology. In three main theories he has in a visionary
way elucidated essential questions concerning specificity,
development and regulation of the immune response. The
natural-selection theory regarding antibody formation
breaks with old views on the immune response and is a
starting point of modern cellular immunology. His second
theory explains how the cells of the immune system which
mature in the thymus gland develop under the influence of
the transplantation antigens of the host. The third, and
most important theory, predicts how the immune response is
regulated by a complicated network consisting of antibodies
and anti-anti-bodies. The principles of the network theory
are beginning to be exploited in prevention, diagnosis and
treatment of disease.
The hybridoma technique for the production of monoclonal
antibodies represents one of the most important
methodological advances in biomedicine during the 1970s. An
antibody producing cell and all its daughter cells produce
an identical antibody molecule (monoclonal antibody). Since
long scientists nourished the hope that it would become
possible to produce monoclonal antibodies with
predetermined specificities. This dream became a reality in
1975 when Georges J.F. Köhler and César
Milstein described the hybridoma technique for
production of monoclonal antibodies. They immortalized
antibody producing cells by fusing them with tumour cells.
The method allows unlimited production of monoclonal
antibodies with predetermined specificity. Monoclonal
antibodies has opened up completely new fields for
theoretical and applied biomedical research and allows
precise diagnosis and also treatment of disease.
The most important task for the immune system is to defend
the body against bacteria, virus and other microorganisms.
The specific defense is exerted by a subgroup of white
blood cells (lymphocytes). The immune system needs to
recognize and react specifically with a large number of
foreign substances (antigens). How the lymphocytes develop
these vital properties and how they build up the highly
specialized recognition system of the immune apparatus has
long been an area of intensive research.
Niels K. Jerne is the leading theoretician in immunology
during the last 30 years. In three main theories he has
elucidated central issues concerning specificity,
development and regulation of the immune system in a
comprehensive and convincing way. By his theories Jerne has
outlined the development of modern immunology.
In his Natural-Selection Theory of Antibody
Formation from 1955 Jerne explains the development of a
specific antibody response in the following way. Each
individual has a large number of natural antibodies with
specificities for all antigens towards which the individual
can respond. These antibodies develop already during fetal
life in the absence of external antigens. The foreign
antigen then selects the antibody molecule which has the
best fit. The antigen-antibody binding stimulates the
production of this particular antibody specificity.
Jerne's natural-selection theory contrasted to the dogmatic
views of the antibody response as formulated in the
instruction theories which were prevailing at that time.
According to these theories the antigen serves a template
for the production of antibodies.
In Jerne's natural selection theory it is implied that the
generation of the enormous number of antibody specificities
is independent of exogenous antigens. This view on the
nature of the immune system constitutes the basis for
modern immunology.
The natural-selection theory is mainly concerned with the maturation of the immune system after it has acquired the ability to react with antigen. In the second theory on the Somatic Generation of Immune Recognition set forth in 1971 Jerne explains how the immune system develops from stem cells to mature lymphocytes which can react with antigen. He presupposes that every individual possesses all genes needed for the production of antibodies, and antibody-like molecules, which can bind all strong transplantation antigens of the species. Jerne suggests that lymphocytes mature in the thymus gland and in other lymphoid organs where they are exposed to the transplantation antigens of the individual. Cells which recognize the antigens are stimulated and enter cell division. As mutations accumulate in rapidly dividing cells new immunological specificities may develop. At the same time the specificities of the lymphocytes for self transplantation antigens are weakened. The mature lymphocytes will recognize foreign antigen associated with transplantation antigens. The theory explains how the immune system normally matures through the influence of self antigens. It also offers an explanation for the regulation of immunological specificity by genes belonging to the transplantation system.
In his third main theory, the Network Theory from
1974, Jerne explains how the specific immune response is
regulated. The theory has greatly stimulated research and
led to new insights into the immune system. Recently its
principles have been applied to diagnosis and treatment of
disease.
A basis for the network theory was the observation that
antibodies can elicit anti-antibodies directed against
antigen binding structures on the first antibody (Figure
1). Moreover, anti-antibodies can stimulate the production
of still another generation of antibodies,
anti-anti-antibodies. Essentially, this antibody cascade is
endless successively adding new specific properties to the
immune system. The various antibody generations either
stimulate or suppress the production of one another. Under
normal conditions the network is balanced. When an antigen
is introduced the equilibrium is disturbed. The immune
system tries to restore balance which leads to an immune
response against the antigen.
![]() |
Figure 1. The Network Theory. Antibody 1 (Ak-1)
has a structure in its variable (V) region which can bind
the antigen. The V-region of Ak-1 contains unique
structures which stimulate the production of various
anti-antibodies (Ak-2). Some Ak-2 express V-region
structures which mimic the antigen and which therefore can
stimulate Ak-1 production.
Each antibody generation induces the production of still
another and larger set of anti-antibodies in a cascade-like
manner. The various sets of antibodies stimulate or
suppress the production of each other in a complex network.
Under normal conditions the network is balanced. However,
the equilibrium is disturbed when an antigen is introduced
and binds to Ak-1. The immune system attempts to restore
the balance, i.e. it leads to an immune response.
Some examples where the network theory has been applied to
experimental and clinical medicine are given in the
following.
1. Infectious diseases. Anti-antibodies have been
used in animals as a kind of vaccine against parasitic
infections (trypanosomiasis), urinary tract infections,
hepatitis and other infectious diseases.
2. Allergy. Anti-pollen antibodies may elicit
allergic symptoms when an allergic person is exposed to
pollen. The production of anti-pollen antibodies has been
prevented in animals by anti-antibodies.
3. Autoimmune disease. Autoimmune disease may be
caused by antibodies directed against the body's own
tissues. Experimental autoimmune disease has been
successfully treated with anti-antibodies.
4. Transplantation. Anti-antiimmunity may be
important in organ transplantation by contributing to
immunological tolerance against antigen on the foreign
graft.
5. Endocrinology. Anti-antibodies against hormones
and hormone receptors may prevent binding of the hormone to
the receptors. This has been described for insulin and its
receptor.
6. Tumours. Anti-antibodies have been attempted as
treatment of certain tumours of the human immune
system.
Besides gene technology, which has already been honoured by
several Nobel Prizes, the hybridoma technique represents
the most important methodological advance within the field
of biomedicine during the 1970s. The development of this
technique is based on several observations concerning basic
biological phenomena.
There are cells in the body - immune lymphocytes - which
can produce millions of different antibodies. However, each
single cell can only produce antibodies with a certain
predetermined specificity. A prerequisite for the formation
of a multitude of antibodies is, therefore, the existence
of an excess of lymphocytes. If the body is exposed to a
certain foreign antigen there may be stimulation of a
lymphocyte which fortuitously has been endowed with the
capacity to identify this particular antigen. This
lymphocyte then starts to divide and forms a clone of cells
which produces identical - monoclonal - antibodies.
The development of a clone of cells in connection with a
normal immune response occurs under carefully controlled
conditions. In rare cases, however, the body loses control
over a clone of antibody producing cells. This may lead to
formation of a special type of tumour (myeloma). Myeloma
cells usually retain their capacity to produce a certain
antibody, but because of the accidental emergence of the
tumour one normally does not know with which antigen this
antibody reacts.
White blood cells responsible for producing antibodies are
highly specialized cells. As a consequence they lack
capacity to survive for a longer time if they are removed
from the body and incubated in a tissue culture medium. In
contrast, myeloma cells can occasionally be cultivated
continuously. Since long, biomedical research workers have
nourished the dream to be able to propagate clones of cells
which produce antibodies with predetermined specificity.
This dream materialized when Georges J.F. Köhler and
César Milstein in 1975 introduced the so-called
hybridoma technology for production of monclonal
antibodies. The principle features of the hybridoma
technology is as follows (Figure 2).
![]() |
Figure 2. Principle steps in the
production of a hybridoma. Spleen cells are prepared from
animals, usually mice, which have been immunized with a
selected antigen. These cells are then fused with myeloma
cells maintained in culture in the laboratory. The product
of this fusion is referred to as a hybridoma. Surprisingly,
a hybrid of two cells can survive and also continue to
divide. In this particular hybrid the myeloma cells
contribute the capacity for survival, whereas the spleen
cells direct the synthesis of antibodies with the
preselected specificity. By special arrangements it is
possible to achieve a multiplication of hybridoma cells but
not of isolated myeloma cells. The hybrids obtained are
propagated in a highly diluted state so that colonies
deriving from single hybrid cells can be isolated. By use
of a sensitive method the clones which produce the specific
antibodies are identified. A particular hybridoma can then
be used for future, unlimited production of a highly
specific antibody.
The availability of monoclonal antibodies has opened
completely new possibilities for basic as well as applied
biomedical research. The following examples of the use of
monoclonal antibodies can be given.
1. Detailed studies of the distribution of different
functions in different parts of antigen molecules.
These studies may concern building elements of infectious
agents; cell products such as enzymes and hormones; surface
structures of cells etc. The mapping of variations in the
surface components of influenza virus which explain the
occurrence of repeated infections is one example.
2. High degree purification of substances, e.g.
interferon, by taking advantage of the unique capacity
displayed by a particular monoclonal antibody to bind to a
certain antigen. In this case one uses a technique referred
to as affinity chromatography.
3. Diagnostic characterization of diseases by
identification of special structures on the surface or on
the inside of cells. Hereby it is possible to distinguish
between different forms of tumours and follow the
development of tumours. Furthermore, it is possible to
distinguish between different kinds of normal white blood
cells. This is of importance for the characterization of
certain immune deficiency conditions as seen e.g. in
connection with the disease AIDS (acquired immune
deficiency syndrome).
Diseases caused by infectious agents can also be diagnosed
by use of monoclonal antibodies. Thus, virus infected cells
and bacteria or parasites inside or outside cells can be
identified with a unique degree of specificity.
4. Treatment of diseases. Monoclonal antibodies
against specialized white blood cells have been used with
some success in connection with transplantation. There may
also be possibilities to use monoclonal antibodies for
treatment of tumours.
References
C. Milstein: Monoclonal
Antibodies. Scientific American 1980, vol. 243,
pp. 56-65.
Hybridomas: The Making of a
Revolution. Science 1982, vol. 215, pp.
1073-1075.
Odödliga hybridceller -
fabriker för tillverkning av monoklonala
antikroppar. En av vår tids mest lovande medicinska
upptäckter. Läkartidningen 1982, vol.
79, pp. 3545-3546.
L. Å. Hanson H. Wigzell:
Immunologi, Del I. Teori. Almqvist & Wiksell,
Stockholm, 1983.
M. Harboe & J. B. Natvig:
Medisinsk Immunologi. Grøndahl & Søn
Trykkeri A.s., Oslo, 1977.